Susan Alexander - Biogen President
| BIIB34 Stock | BRL 171.36 0.00 0.00% |
President
Ms. Susan H. Alexander, Esq., is Executive Vice President, Chief Legal Officer and Secretary of the Company. Prior to that, from March 2017 to March 2018, Ms. Alexander served as our Executive Vice President, Chief Legal, Corporationrationrate Services and Secretary, from December 2011 to March 2017, as our Executive Vice President, Chief Legal Officer and Secretary and from 2006 to December 2011, as our Executive Vice President, General Counsel and Corporationrationrate Secretary. Prior to joining Biogen, Ms. Alexander served as the Senior Vice President, General Counsel and Corporationrationrate Secretary of PAREXEL International Corporationrationration, a biopharmaceutical services company, from 2003 to January 2006. From 2001 to 2003 Ms. Alexander served as General Counsel of IONA Technologies, a software company. From 1995 to 2001 Ms. Alexander served as Counsel at Cabot Corporationrationration, a specialty chemicals and performance materials company. Prior to that, Ms. Alexander was a partner at the law firms of Hinckley, Allen Snyder and Fine Ambrogne. since 2018.
| Age | 61 |
| Tenure | 6 years |
| Phone | 617 679 2000 |
| Web | https://www.biogen.com |
Biogen Management Efficiency
The company has return on total asset (ROA) of 0.076 % which means that it generated a profit of $0.076 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2023 %, meaning that it generated $0.2023 on every $100 dollars invested by stockholders. Biogen's management efficiency ratios could be used to measure how well Biogen manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Bret Taylor | salesforce inc | 43 | |
| Cynthia Robbins | salesforce inc | 44 | |
| Troyen Brennan | CVS Health | 62 | |
| Robert Kraft | CVS Health | 46 | |
| David Denton | CVS Health | 51 | |
| Brett Hart | United Airlines Holdings | 53 | |
| Derica Rice | CVS Health | 52 | |
| Eva Boratto | CVS Health | 50 | |
| Lisa Bisaccia | CVS Health | 60 | |
| John Cummings | salesforce inc | N/A | |
| Maria Martinez | salesforce inc | 59 | |
| Jonathan Roberts | CVS Health | 61 | |
| Kevin Hourican | CVS Health | N/A | |
| Amy Weaver | salesforce inc | 55 | |
| Mark Hawkins | salesforce inc | 58 | |
| Andrew Sussman | CVS Health | 50 | |
| Joyner | CVS Health | 51 | |
| Stephen Gold | CVS Health | 56 | |
| Alexandre Dayon | salesforce inc | 55 | |
| Thomas Moriarty | CVS Health | 59 | |
Management Performance
| Return On Equity | 0.2 | |||
| Return On Asset | 0.076 |
Biogen Inc Leadership Team
Elected by the shareholders, the Biogen's board of directors comprises two types of representatives: Biogen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biogen. The board's role is to monitor Biogen's management team and ensure that shareholders' interests are well served. Biogen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biogen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Viehbacher, CEO Pres | ||
| Robin Kramer, Chief Accounting Officer, Vice President | ||
| Jesus Mantas, Director | ||
| Paul McKenzie, Executive Vice President - Pharmaceutical Operations & Technology | ||
| Richard Mulligan, Independent Director | ||
| Michel Vounatsos, CEO, Director | ||
| Sanjay Jariwala, Senior Vice President - Worldwide Medical | ||
| Susan Esq, Chief VP | ||
| Alfred Sandrock, Executive Vice President - Neurology Discovery and Development and Chief Medical Officer | ||
| Alexander Denner, Independent Director | ||
| Natacha Gassenbach, Chief Affairs | ||
| JeanPaul Kress, Executive Vice President and Presidentident - International and Head of Global Therapeutic Operations | ||
| Eric Rowinsky, Independent Director | ||
| William Hawkins, Director | ||
| Adriana Karaboutis, Executive Vice President - Technology , Business Solutions and Corporate Affairs | ||
| Mark Hernon, Senior Vice President CIO | ||
| Kenneth Pietro, Executive Vice President - Human Resources | ||
| John Chiminski, Director | ||
| Stephen Sherwin, Independent Director | ||
| Caroline Dorsa, Independent Director | ||
| Ginger Gregory, Chief Human Resource Officer, Executive Vice President | ||
| Michael Ehlers, Executive Vice President Head - Research and Development | ||
| Chirfi Guindo, Executive Vice President Head of Global Marketing, Market Access and Customer Innovation | ||
| Susan Alexander, Executive Vice President Chief Legal Officer and Corporate Secretary | ||
| Catherine Steele, Senior Vice President - Corporate Affairs | ||
| Daniel Karp, Executive Vice President - Corporate Development | ||
| Anirvan Ghosh, Senior Vice President - Research and Early Development | ||
| Michael CPA, Ex CFO | ||
| Nancy Leaming, Independent Director | ||
| Nicole Murphy, Head Technology | ||
| Michael Hencke, Head Relations | ||
| Camille Lee, Senior Vice President - Alzheimer's Therapeutic Area | ||
| Lynn Schenk, Independent Director | ||
| Brian Posner, Independent Director | ||
| Gregory Covino, Chief Accounting Officer, Vice President - Finance | ||
| Anabella Villalobos, Senior Vice President - Biotherapeutic & Medicinal Sciences (BTMS) | ||
| Stelios Papadopoulos, Independent Chairman of the Board | ||
| Robert Pangia, Independent Director | ||
| Jeffrey Capello, CFO, Executive Vice President |
Biogen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biogen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.2 | |||
| Return On Asset | 0.076 | |||
| Profit Margin | 0.28 % | |||
| Operating Margin | 0.29 % | |||
| Current Valuation | 230.79 B | |||
| Shares Outstanding | 867.48 M | |||
| Price To Earning | 6.38 X | |||
| Price To Book | 3.28 X | |||
| Price To Sales | 21.53 X | |||
| Revenue | 10.98 B |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Biogen in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Biogen's short interest history, or implied volatility extrapolated from Biogen options trading.
Pair Trading with Biogen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biogen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biogen will appreciate offsetting losses from the drop in the long position's value.Moving against Biogen Stock
| 0.92 | S1MF34 | Sumitomo Mitsui Financial | PairCorr |
| 0.89 | JPMC34 | JPMorgan Chase | PairCorr |
| 0.87 | M1UF34 | Mitsubishi UFJ Financial | PairCorr |
| 0.86 | TSMC34 | Taiwan Semiconductor | PairCorr |
| 0.85 | NMRH34 | Nomura Holdings | PairCorr |
The ability to find closely correlated positions to Biogen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biogen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biogen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biogen Inc to buy it.
The correlation of Biogen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biogen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biogen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biogen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Biogen Inc information on this page should be used as a complementary analysis to other Biogen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Complementary Tools for Biogen Stock analysis
When running Biogen's price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |